Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BR3005 (Empagliflozin + Metformin) FDC vs Co-administration
NCT06289920Phase 1Completed
- Sponsor
- Boryung
- Start
- Mar 2024
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boryung. Primary endpoints: Area Under the Curve tau and Maximum Plasma Concentration. Started Mar 2024; status: completed.
02
Drugs
empagliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06289920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06289920.